HC Wainwright Raises OptiNose (NASDAQ:OPTN) Price Target to $18.00

OptiNose (NASDAQ:OPTN) had its price target lifted by HC Wainwright from $5.00 to $18.00 in a research note issued to investors on Friday, Marketbeat reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for OptiNose’s FY2029 earnings at $1.41 EPS.

Separately, Piper Sandler cut their target price on shares of OptiNose from $45.00 to $15.00 and set an “overweight” rating for the company in a research report on Wednesday, November 13th.

OptiNose Stock Performance

Shares of NASDAQ:OPTN opened at $6.50 on Friday. OptiNose has a 52-week low of $4.82 and a 52-week high of $31.50. The firm has a fifty day moving average of $7.81 and a 200 day moving average of $11.82. The firm has a market capitalization of $65.39 million, a PE ratio of -23.21 and a beta of -0.15.

Institutional Trading of OptiNose

Several institutional investors have recently added to or reduced their stakes in OPTN. Massachusetts Financial Services Co. MA boosted its position in OptiNose by 2.9% during the second quarter. Massachusetts Financial Services Co. MA now owns 2,920,309 shares of the company’s stock valued at $3,037,000 after buying an additional 81,233 shares during the period. XTX Topco Ltd purchased a new stake in shares of OptiNose during the second quarter worth about $88,000. Great Point Partners LLC boosted its holdings in shares of OptiNose by 56.2% during the second quarter. Great Point Partners LLC now owns 13,727,097 shares of the company’s stock worth $14,276,000 after purchasing an additional 4,940,779 shares during the period. Squarepoint Ops LLC boosted its holdings in shares of OptiNose by 173.7% during the second quarter. Squarepoint Ops LLC now owns 171,610 shares of the company’s stock worth $178,000 after purchasing an additional 108,903 shares during the period. Finally, Nantahala Capital Management LLC boosted its holdings in shares of OptiNose by 442.3% during the second quarter. Nantahala Capital Management LLC now owns 13,418,740 shares of the company’s stock worth $14,425,000 after purchasing an additional 10,944,444 shares during the period. 85.60% of the stock is currently owned by hedge funds and other institutional investors.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.